Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel Free BTSG Stock Alerts

BrightSpring Health Services (BTSG) Financials

BrightSpring Health Services logo
$61.20 -0.23 (-0.37%)
As of 02:29 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BrightSpring Health Services

Annual Income Statements for BrightSpring Health Services

This table shows BrightSpring Health Services' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -54 -155 -18 191
Consolidated Net Income / (Loss)		 -54 -157 -21 189
Net Income / (Loss) Continuing Operations		 -54 -182 -69 105
Total Pre-Tax Income 		-46 -214 -95 138
Total Operating Income		 188 58 108 295
Total Gross Profit		 1,354 1,139 1,266 1,518
Total Revenue		 7,721 7,691 10,072 12,911
Operating Revenue		 7,721 7,691 10,072 12,911
Total Cost of Revenue		 6,366 6,552 8,806 11,393
Operating Cost of Revenue		 6,366 6,552 8,806 11,393
Total Operating Expenses		 1,166 1,081 1,158 1,223
Selling, General & Admin Expense		 1,126 1,081 1,158 1,223
Total Other Income / (Expense), net		 -234 -272 -203 -157
Interest Expense		 234 272 203 157
Income Tax Expense		 8.47 -32 -26 33
Net Income / (Loss) Discontinued Operations		 - 25 48 84
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.31 -2.23 -2.46 -1.55
Basic Earnings per Share		 ($0.46) ($1.31) ($0.09) $0.94
Weighted Average Basic Shares Outstanding		 117.84M 117.87M 193.00M 202.56M
Diluted Earnings per Share		 ($0.46) ($1.31) ($0.09) $0.87
Weighted Average Diluted Shares Outstanding		 117.84M 117.87M 193.00M 219.77M
Weighted Average Basic & Diluted Shares Outstanding		 - - 174.97M 193.54M

Quarterly Income Statements for BrightSpring Health Services

This table shows BrightSpring Health Services' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -6.54 -46 20 -8.23 16 30 28 56 77 149 84
Consolidated Net Income / (Loss)		 -7.20 -46 19 -8.98 15 29 28 55 77 149 84
Net Income / (Loss) Continuing Operations		 -7.20 -56 8.49 -26 15 9.22 8.54 37 50 74 87
Total Pre-Tax Income 		-15 -83 -4.63 -18 24 8.98 9.78 50 70 83 94
Total Operating Income		 68 -15 39 29 79 51 49 88 108 121 130
Total Gross Profit		 369 292 312 323 422 338 375 392 413 482 493
Total Revenue		 2,375 2,286 2,438 2,601 3,053 2,878 3,148 3,334 3,551 3,614 3,873
Operating Revenue		 2,375 2,286 2,438 2,601 3,053 2,878 3,148 3,334 3,551 3,614 3,873
Total Cost of Revenue		 2,006 1,993 2,126 2,278 2,631 2,540 2,773 2,942 3,138 3,131 3,380
Operating Cost of Revenue		 2,006 1,993 2,126 2,278 2,631 2,540 2,773 2,942 3,138 3,131 3,380
Total Operating Expenses		 300 308 274 294 343 288 326 304 304 361 362
Selling, General & Admin Expense		 300 308 274 294 343 288 326 304 304 361 362
Total Other Income / (Expense), net		 -83 -67 -43 -47 -55 -42 -39 -38 -39 -39 -37
Interest Expense		 83 67 43 47 55 42 39 38 39 39 37
Income Tax Expense		 -7.59 -27 -13 8.16 8.78 -0.24 1.24 12 20 8.55 6.91
Net Income / (Loss) Discontinued Operations		 - 9.64 11 17 - 20 19 18 28 74 -2.40
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.66 -0.64 -0.48 -0.75 -0.60 -0.53 -0.67 -0.60 0.24 -0.16 -0.08
Basic Earnings per Share		 ($0.05) ($0.26) $0.10 ($0.04) $0.11 $0.15 $0.14 $0.27 $0.38 $0.73 $0.41
Weighted Average Basic Shares Outstanding		 117.87M 175.53M 197.52M 198.49M 193.00M 201.01M 201.81M 203.49M 202.56M 204.71M 206.04M
Diluted Earnings per Share		 ($0.05) ($0.26) $0.10 ($0.04) $0.11 $0.14 $0.13 $0.26 $0.34 $0.67 $0.38
Weighted Average Diluted Shares Outstanding		 117.87M 175.53M 208.99M 198.49M 193.00M 214.93M 216.34M 217.98M 219.77M 221.32M 220.28M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 171.32M 171.46M 174.13M 174.97M 174.25M 177.15M 180.35M 193.54M 193.92M 197.86M

Annual Cash Flow Statements for BrightSpring Health Services

This table details how cash moves in and out of BrightSpring Health Services' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -33 -0.56 48 27
Net Cash From Operating Activities		 -4.65 211 24 490
Net Cash From Continuing Operating Activities		 -4.65 211 24 490
Net Income / (Loss) Continuing Operations		 -54 -157 -21 189
Consolidated Net Income / (Loss)		 -54 -157 -21 189
Depreciation Expense		 204 202 204 164
Amortization Expense		 20 21 12 11
Non-Cash Adjustments To Reconcile Net Income		 78 38 124 129
Changes in Operating Assets and Liabilities, net		 -252 107 -296 -3.70
Net Cash From Investing Activities		 45 -134 -140 -305
Net Cash From Continuing Investing Activities		 45 -134 -140 -305
Purchase of Property, Plant & Equipment		 -70 -74 -81 -95
Acquisitions		 -42 -63 -60 -205
Other Investing Activities, net		 2.14 2.15 0.47 -5.03
Net Cash From Financing Activities		 -74 -77 165 -158
Net Cash From Continuing Financing Activities		 -74 -77 165 -158
Repayment of Debt		 -41 -30 -3,443 -50
Repurchase of Preferred Equity		 0.00 -10 0.00 0.00
Repurchase of Common Equity		 0.00 -0.65 -2.97 -48
Issuance of Debt		 -17 -24 2,968 -63
Issuance of Common Equity		 0.23 1.33 658 25
Other Financing Activities, net		 -15 -13 -15 -21
Cash Interest Paid		 213 304 211 184
Cash Income Taxes Paid		 29 37 25 27

Quarterly Cash Flow Statements for BrightSpring Health Services

This table details how cash moves in and out of BrightSpring Health Services' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 1.43 45 -33 11 25 -8.61 18 71 -53 800 -338
Net Cash From Operating Activities		 162 -79 -15 27 91 102 49 108 232 123 44
Net Cash From Continuing Operating Activities		 162 -79 -15 27 91 102 49 108 232 123 44
Net Income / (Loss) Continuing Operations		 -7.20 -46 19 -8.98 15 29 28 55 77 149 84
Consolidated Net Income / (Loss)		 -7.20 -46 19 -8.98 15 29 28 55 77 149 84
Depreciation Expense		 51 49 50 51 55 42 42 41 40 39 41
Amortization Expense		 5.23 4.45 2.49 2.54 2.63 2.75 2.79 2.84 2.86 2.82 2.95
Non-Cash Adjustments To Reconcile Net Income		 7.49 46 21 27 30 28 55 20 26 -96 32
Changes in Operating Assets and Liabilities, net		 106 -132 -108 -44 -12 -0.72 -78 -11 86 29 -117
Net Cash From Investing Activities		 -17 -31 -58 -36 -16 -24 -23 -24 -234 747 -28
Net Cash From Continuing Investing Activities		 -17 -31 -58 -36 -16 -24 -23 -24 -234 747 -28
Purchase of Property, Plant & Equipment		 -17 -22 -24 -20 -15 -18 -24 -16 -38 -22 -29
Other Investing Activities, net		 0.36 0.27 0.27 0.36 -0.43 0.20 1.18 -6.45 0.04 0.23 0.83
Net Cash From Financing Activities		 -144 155 40 20 -50 -86 -8.24 -13 -50 -70 -354
Net Cash From Continuing Financing Activities		 -144 155 40 20 -50 -86 -8.24 -13 -50 -70 -354
Repayment of Debt		 -7.58 -3,453 -2,527 -14 -16 -12 -12 -14 51 -12 -312
Repurchase of Common Equity		 -0.33 -0.63 -0.33 -2.02 - -5.10 - - -43 -60 -60
Issuance of Common Equity		 0.74 656 0.40 0.13 1.00 0.35 8.72 5.62 11 12 20
Other Financing Activities, net		 -4.42 -3.08 -4.13 -6.22 -1.20 -6.17 -5.03 -4.51 -5.58 -9.76 -2.67
Cash Interest Paid		 78 60 51 54 46 54 42 42 46 43 33
Cash Income Taxes Paid		 1.86 11 13 0.62 0.64 0.25 13 1.83 12 0.40 156

Annual Balance Sheets for BrightSpring Health Services

This table presents BrightSpring Health Services' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5,533 5,926 6,413
Total Current Assets		 1,457 1,893 2,894
Cash & Equivalents		 13 61 88
Accounts Receivable		 882 903 990
Inventories, net		 403 637 815
Prepaid Expenses		 159 161 119
Other Current Nonoperating Assets		 - 131 882
Plant, Property, & Equipment, net		 246 181 205
Total Noncurrent Assets		 3,830 3,853 3,315
Goodwill		 2,608 2,364 2,546
Intangible Assets		 881 595 558
Other Noncurrent Operating Assets		 340 200 211
Total Liabilities & Shareholders' Equity		 5,533 5,926 6,413
Total Liabilities		 4,920 4,275 4,527
Total Current Liabilities		 1,248 1,428 1,849
Short-Term Debt		 32 49 52
Accounts Payable		 642 924 1,218
Accrued Expenses		 492 296 333
Other Current Liabilities		 82 42 50
Other Current Nonoperating Liabilities		 - 118 196
Total Noncurrent Liabilities		 3,672 2,846 2,678
Long-Term Debt		 3,332 2,562 2,455
Capital Lease Obligations		 224 136 150
Noncurrent Deferred & Payable Income Tax Liabilities		 24 0.00 6.18
Other Noncurrent Operating Liabilities		 92 71 67
Redeemable Noncontrolling Interest		 27 3.73 11
Total Equity & Noncontrolling Interests		 585 1,648 1,875
Total Preferred & Common Equity		 585 1,648 1,875
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 585 1,648 1,875
Common Stock		 773 1,869 1,956
Retained Earnings		 -200 -222 -75
Accumulated Other Comprehensive Income / (Loss)		 13 1.42 -6.69
Noncontrolling Interest		 0.67 0.00 0.07

Quarterly Balance Sheets for BrightSpring Health Services

This table presents BrightSpring Health Services' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 5,656 5,605 5,786 5,847 5,944 6,049 6,213 5,986
Total Current Assets		 1,573 1,522 1,710 2,528 2,648 2,780 2,689 2,470
Cash & Equivalents		 58 25 36 52 70 140 889 550
Accounts Receivable		 991 985 1,026 975 973 1,013 1,114 1,139
Inventories, net		 374 374 478 534 625 639 560 575
Prepaid Expenses		 150 138 170 131 129 124 127 205
Other Current Nonoperating Assets		 - - - 836 850 864 0.00 0.00
Plant, Property, & Equipment, net		 246 246 249 177 178 175 202 214
Total Noncurrent Assets		 3,837 3,838 3,828 3,141 3,118 3,094 3,322 3,302
Goodwill		 2,609 2,626 2,673 2,370 2,370 2,371 2,534 2,535
Intangible Assets		 856 851 842 568 544 522 537 514
Other Noncurrent Operating Assets		 361 338 306 201 200 202 252 252
Total Liabilities & Shareholders' Equity		 5,656 5,605 5,786 5,847 5,944 6,049 6,213 5,986
Total Liabilities		 4,081 3,999 4,167 4,156 4,198 4,228 4,223 3,928
Total Current Liabilities		 1,245 1,145 1,264 1,458 1,505 1,550 1,548 1,556
Short-Term Debt		 49 49 49 49 51 52 53 41
Accounts Payable		 656 669 784 868 965 954 1,091 1,091
Accrued Expenses		 452 347 349 303 253 304 352 372
Other Current Liabilities		 89 80 82 42 42 43 52 52
Other Current Nonoperating Liabilities		 - - - 196 194 197 0.00 0.00
Total Noncurrent Liabilities		 2,836 2,854 2,903 2,699 2,693 2,679 2,675 2,372
Long-Term Debt		 2,515 2,564 2,609 2,489 2,478 2,465 2,445 2,149
Capital Lease Obligations		 24 220 221 137 141 139 150 145
Noncurrent Deferred & Payable Income Tax Liabilities		 0.00 0.00 0.00 0.00 0.00 10 1.17 0.64
Other Noncurrent Operating Liabilities		 297 71 74 73 74 64 79 77
Redeemable Noncontrolling Interest		 6.28 5.94 4.13 3.32 2.82 2.36 11 9.42
Total Equity & Noncontrolling Interests		 1,568 1,600 1,615 1,687 1,743 1,819 1,979 2,049
Total Preferred & Common Equity		 1,567 1,600 1,615 1,687 1,743 1,819 1,979 2,049
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,567 1,600 1,615 1,687 1,743 1,819 1,979 2,049
Common Stock		 1,790 1,807 1,850 1,882 1,912 1,933 1,966 2,006
Retained Earnings		 -246 -226 -234 -193 -164 -109 14 38
Accumulated Other Comprehensive Income / (Loss)		 23 19 -0.71 -1.87 -4.33 -6.29 -1.27 4.19
Noncontrolling Interest		 0.52 0.38 0.20 -0.13 -0.28 0.09 0.06 0.07

Annual Metrics And Ratios for BrightSpring Health Services

This table displays calculated financial ratios and metrics derived from BrightSpring Health Services' official financial filings.

Metric 2022 2023 2024 2025
Period end date 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - -
Revenue Growth		 0.00% 14.32% 27.65% 28.18%
EBITDA Growth		 0.00% -10.14% 14.18% 45.06%
EBIT Growth		 0.00% -21.64% 40.22% 173.50%
NOPAT Growth		 0.00% -21.64% 40.22% 196.83%
Net Income Growth		 0.00% -189.26% 86.92% 1,021.56%
EPS Growth		 0.00% -184.78% 93.13% 1,066.67%
Operating Cash Flow Growth		 0.00% 4,630.05% -88.72% 1,961.79%
Free Cash Flow Firm Growth		 0.00% 0.00% 102.61% -69.59%
Invested Capital Growth		 0.00% 0.00% 0.91% 1.53%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -2.94%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -11.47%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -13.44%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -15.74%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 48.68%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 35.94%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 40.36%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -84.16%
Invested Capital Q/Q Growth		 0.00% 0.00% -5.28% 2.71%
Profitability Metrics		 - - - -
Gross Margin		 17.54% 16.24% 14.10% 11.76%
EBITDA Margin		 5.34% 4.20% 3.75% 3.65%
Operating Margin		 2.43% 1.67% 1.83% 2.29%
EBIT Margin		 2.43% 1.67% 1.83% 2.29%
Profit (Net Income) Margin		 -0.70% -1.78% -0.18% 1.46%
Tax Burden Percent		 118.50% 88.40% 59.07% 137.10%
Interest Burden Percent		 -24.36% -120.54% -16.83% 46.72%
Effective Tax Rate		 0.00% 0.00% 0.00% 24.03%
Return on Invested Capital (ROIC)		 0.00% 4.92% 3.43% 6.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -9.62% -1.93% 4.21%
Return on Net Nonoperating Assets (RNNOA)		 0.00% -56.13% -5.25% 4.69%
Return on Equity (ROE)		 0.00% -51.21% -1.81% 10.69%
Cash Return on Invested Capital (CROIC)		 0.00% -195.08% 2.53% 4.48%
Operating Return on Assets (OROA)		 0.00% 2.66% 3.60% 4.79%
Return on Assets (ROA)		 0.00% -2.83% -0.36% 3.07%
Return on Common Equity (ROCE)		 0.00% -48.88% -1.79% 10.65%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -26.82% -1.25% 0.00%
Net Operating Profit after Tax (NOPAT)		 131 103 144 224
NOPAT Margin		 1.70% 1.17% 1.28% 1.74%
Net Nonoperating Expense Percent (NNEP)		 0.00% 14.54% 5.37% 1.78%
Return On Investment Capital (ROIC_SIMPLE)		 - 2.47% 3.37% 4.95%
Cost of Revenue to Revenue		 82.46% 83.76% 85.90% 88.24%
SG&A Expenses to Revenue		 14.58% 14.58% 12.27% 9.47%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 15.11% 14.58% 12.27% 9.47%
Earnings before Interest and Taxes (EBIT)		 188 147 206 295
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 412 370 423 471
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 0.00 1.19 1.80 3.60
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.09 0.08 0.26 0.52
Price to Earnings (P/E)		 0.00 0.00 0.00 35.42
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 2.82%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.03 1.31 2.48
Enterprise Value to Revenue (EV/Rev)		 0.00 0.49 0.49 0.72
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 11.60 13.11 19.83
Enterprise Value to EBIT (EV/EBIT)		 0.00 29.19 26.86 31.62
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 41.70 38.37 41.62
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 20.38 233.17 19.04
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 52.08 55.71
Leverage & Solvency		 - - - -
Debt to Equity		 0.00 5.86 1.60 1.41
Long-Term Debt to Equity		 0.00 5.81 1.57 1.38
Financial Leverage		 0.00 5.84 2.72 1.11
Leverage Ratio		 0.00 9.03 5.06 3.49
Compound Leverage Factor		 0.00 -10.89 -0.85 1.63
Debt to Total Capital		 0.00% 85.42% 61.48% 58.49%
Short-Term Debt to Total Capital		 0.00% 0.77% 1.14% 1.15%
Long-Term Debt to Total Capital		 0.00% 84.65% 60.34% 57.33%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.66% 0.09% 0.25%
Common Equity to Total Capital		 0.00% 13.92% 38.44% 41.27%
Debt to EBITDA		 0.00 9.69 6.23 5.65
Net Debt to EBITDA		 0.00 9.65 6.09 5.46
Long-Term Debt to EBITDA		 0.00 9.60 6.12 5.53
Debt to NOPAT		 0.00 34.83 18.24 11.85
Net Debt to NOPAT		 0.00 34.70 17.82 11.45
Long-Term Debt to NOPAT		 0.00 34.52 17.91 11.61
Altman Z-Score		 0.00 1.76 2.47 3.24
Noncontrolling Interest Sharing Ratio		 0.00% 4.54% 1.39% 0.42%
Liquidity Ratios		 - - - -
Current Ratio		 0.00 1.17 1.33 1.57
Quick Ratio		 0.00 0.72 0.76 0.58
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4,085 106 168
Operating Cash Flow to CapEx		 -6.64% 286.67% 29.38% 513.35%
Free Cash Flow to Firm to Interest Expense		 0.00 -12.58 0.44 1.07
Operating Cash Flow to Interest Expense		 -0.02 0.65 0.10 3.12
Operating Cash Flow Less CapEx to Interest Expense		 -0.32 0.42 -0.24 2.51
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 1.60 1.97 2.09
Accounts Receivable Turnover		 0.00 10.01 11.80 13.64
Inventory Turnover		 0.00 18.35 18.55 15.70
Fixed Asset Turnover		 0.00 35.89 45.41 67.02
Accounts Payable Turnover		 0.00 11.52 12.23 10.64
Days Sales Outstanding (DSO)		 0.00 36.46 30.94 26.75
Days Inventory Outstanding (DIO)		 0.00 19.89 19.67 23.26
Days Payable Outstanding (DPO)		 0.00 31.68 29.85 34.31
Cash Conversion Cycle (CCC)		 0.00 24.67 20.77 15.70
Capital & Investment Metrics		 - - - -
Invested Capital		 0.00 4,188 4,226 3,769
Invested Capital Turnover		 0.00 4.22 2.68 3.45
Increase / (Decrease) in Invested Capital		 0.00 4,188 38 57
Enterprise Value (EV)		 0.00 4,296 5,543 9,335
Market Capitalization		 693 693 2,965 6,754
Book Value per Share		 $0.00 $4.96 $9.46 $10.40
Tangible Book Value per Share		 $0.00 ($24.65) ($10.54) ($6.81)
Total Capital		 0.00 4,201 4,287 4,544
Total Debt		 0.00 3,588 2,636 2,658
Total Long-Term Debt		 0.00 3,556 2,587 2,605
Net Debt		 0.00 3,575 2,574 2,569
Capital Expenditures (CapEx)		 70 74 81 95
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 227 452 1,009
Debt-free Net Working Capital (DFNWC)		 0.00 240 513 1,097
Net Working Capital (NWC)		 0.00 208 465 1,045
Net Nonoperating Expense (NNE)		 186 260 165 35
Net Nonoperating Obligations (NNO)		 0.00 3,575 2,574 1,883
Total Depreciation and Amortization (D&A)		 224 223 217 176
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 2.58% 4.01% 7.82%
Debt-free Net Working Capital to Revenue		 0.00% 2.72% 4.56% 8.50%
Net Working Capital to Revenue		 0.00% 2.36% 4.12% 8.09%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.09) $0.94
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 193.00M 202.56M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.09) $0.87
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 193.00M 219.77M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 174.97M 193.54M
Normalized Net Operating Profit after Tax (NOPAT)		 160 103 144 224
Normalized NOPAT Margin		 2.07% 1.17% 1.28% 1.74%
Pre Tax Income Margin		 -0.59% -2.01% -0.31% 1.07%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 0.80 0.45 0.86 1.88
NOPAT to Interest Expense		 0.56 0.32 0.60 1.43
EBIT Less CapEx to Interest Expense		 0.50 0.23 0.52 1.27
NOPAT Less CapEx to Interest Expense		 0.26 0.09 0.26 0.82
Payout Ratios		 - - - -
Dividend Payout Ratio		 -1.38% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.38% -0.41% -14.45% 25.53%

Quarterly Metrics And Ratios for BrightSpring Health Services

This table displays calculated financial ratios and metrics derived from BrightSpring Health Services' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 193,536,850.00 193,918,398.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 193,536,850.00 193,918,398.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.77 0.43
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 27.03% 26.01% 28.82% 28.56% 25.92% 29.10% 28.17% 29.26% 25.56% 23.05%
EBITDA Growth		 0.00% -42.64% -14.92% 2,870.24% 9.69% 151.48% 2.17% 59.81% 33.12% 70.79% 87.53%
EBIT Growth		 0.00% -84.35% -21.61% 208.78% 15.81% 430.87% 25.62% 201.90% 94.66% 139.36% 168.53%
NOPAT Growth		 0.00% -84.35% 118.27% -1,691.56% 5.36% 585.31% 56.74% 225.91% 203.00% 109.06% 184.74%
Net Income Growth		 0.00% -108.23% 602.86% 93.10% 313.91% 162.54% 41.67% 715.09% 401.95% 412.27% 205.75%
EPS Growth		 0.00% -44.44% 233.33% 96.40% 320.00% 153.85% 30.00% 750.00% 209.09% 378.57% 192.31%
Operating Cash Flow Growth		 0.00% -297.66% 39.59% -19.13% -44.20% 228.84% 422.34% 296.15% 155.55% 21.01% -10.51%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 111.75% 117.48% 119.32% -95.96% -93.08% -104.52%
Invested Capital Growth		 0.00% 0.00% 0.00% 0.00% 0.91% -10.51% -16.41% -17.74% 1.53% 2.05% 4.21%
Revenue Q/Q Growth		 5.23% 0.00% 5.96% 6.47% 5.02% -5.72% 9.37% 5.92% 6.49% 1.78% 7.18%
EBITDA Q/Q Growth		 3,262.11% 0.00% 87.15% -4.34% 24.16% -29.96% -2.57% 41.04% 14.50% 8.55% 6.98%
EBIT Q/Q Growth		 230.64% 0.00% 673.70% -8.93% 39.08% -35.82% -4.30% 80.91% 23.08% 12.34% 7.36%
NOPAT Q/Q Growth		 230.64% 0.00% 2,054.16% -638.71% 107.68% 3.47% -18.59% 56.52% 15.99% 41.45% 10.88%
Net Income Q/Q Growth		 94.47% 0.00% 141.91% -146.20% 271.52% 88.33% -5.06% 100.57% 39.97% 92.20% -43.34%
EPS Q/Q Growth		 95.50% 0.00% 138.46% -140.00% 375.00% 27.27% -7.14% 100.00% 30.77% 97.06% -43.28%
Operating Cash Flow Q/Q Growth		 382.03% 0.00% 80.69% 278.96% 232.57% 12.12% -51.70% 119.94% 114.53% -46.91% -64.28%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -4.69% -19.24% 100.24% 3,824.87% 58.61% 11.91% -97.64% 65.28% -203.69%
Invested Capital Q/Q Growth		 0.00% 0.00% 7.51% 1.10% -5.28% -13.08% 0.42% -0.51% 2.71% -0.55% 2.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 15.53% 14.34% 14.25% 14.04% 13.82% 11.76% 11.91% 11.76% 11.62% 13.34% 12.72%
EBITDA Margin		 5.24% 2.38% 4.21% 3.78% 4.47% 3.32% 2.96% 3.94% 4.24% 4.52% 4.51%
Operating Margin		 2.87% 0.31% 2.29% 1.96% 2.59% 1.76% 1.54% 2.63% 3.04% 3.36% 3.37%
EBIT Margin		 2.87% 0.31% 2.29% 1.96% 2.59% 1.76% 1.54% 2.63% 3.04% 3.36% 3.37%
Profit (Net Income) Margin		 -0.30% -1.80% 0.71% -0.31% 0.50% 1.01% 0.88% 1.66% 2.18% 4.11% 2.17%
Tax Burden Percent		 48.68% 66.57% 194.90% -1,152.89% 63.69% 323.20% 281.64% 111.36% 111.13% 179.41% 90.05%
Interest Burden Percent		 -21.67% -863.75% 15.98% 1.37% 30.60% 17.69% 20.14% 56.47% 64.36% 68.20% 71.72%
Effective Tax Rate		 0.00% 0.00% -94.90% 1,252.89% 36.31% -2.67% 12.66% 24.43% 28.78% 10.32% 7.39%
Return on Invested Capital (ROIC)		 4.24% 0.00% 0.00% 0.00% 4.42% 5.52% 4.18% 6.51% 7.48% 11.08% 11.90%
ROIC Less NNEP Spread (ROIC-NNEP)		 2.70% 0.00% 0.00% 0.00% 3.28% 4.50% 3.55% 6.04% 7.50% 13.20% 9.94%
Return on Net Nonoperating Assets (RNNOA)		 15.78% 0.00% 0.00% 0.00% 8.91% 6.22% 5.04% 8.23% 8.36% 13.42% 9.74%
Return on Equity (ROE)		 20.02% 0.00% 0.00% 0.00% 13.33% 11.74% 9.22% 14.75% 15.84% 24.51% 21.64%
Cash Return on Invested Capital (CROIC)		 -97.54% 0.00% 0.00% 0.00% 2.53% 16.61% 22.27% 26.02% 4.48% 5.88% 5.85%
Operating Return on Assets (OROA)		 4.59% 0.00% 0.00% 0.00% 5.09% 3.64% 3.36% 5.92% 6.37% 7.61% 8.11%
Return on Assets (ROA)		 -0.48% 0.00% 0.00% 0.00% 0.99% 2.08% 1.90% 3.72% 4.56% 9.31% 5.24%
Return on Common Equity (ROCE)		 19.11% 0.00% 0.00% 0.00% 13.14% 11.70% 9.19% 14.72% 15.78% 24.41% 21.57%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% 0.00% 3.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 48 5.65 122 -655 50 52 42 66 77 109 121
NOPAT Margin		 2.01% 0.22% 4.46% -22.54% 1.65% 1.81% 1.35% 1.99% 2.17% 3.01% 3.12%
Net Nonoperating Expense Percent (NNEP)		 1.54% 4.11% 7.28% -45.48% 1.14% 1.02% 0.63% 0.48% -0.02% -2.12% 1.96%
Return On Investment Capital (ROIC_SIMPLE)		 1.14% - - - 1.18% 1.19% 0.96% 1.48% 1.70% 2.35% 2.75%
Cost of Revenue to Revenue		 84.47% 85.66% 85.75% 85.96% 86.18% 88.24% 88.09% 88.24% 88.38% 86.66% 87.28%
SG&A Expenses to Revenue		 12.65% 14.02% 11.96% 12.08% 11.23% 9.99% 10.37% 9.12% 8.57% 9.98% 9.36%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 12.65% 14.02% 11.96% 12.08% 11.23% 9.99% 10.37% 9.12% 8.57% 9.98% 9.36%
Earnings before Interest and Taxes (EBIT)		 68 8.07 62 57 79 51 49 88 108 121 130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 124 61 115 110 137 96 93 131 150 163 175
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.19 0.37 1.22 1.56 1.80 1.88 2.36 2.88 3.60 4.17 6.60
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.08 0.00 0.00 0.00 0.26 0.27 0.33 0.39 0.52 0.60 0.94
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 55.31 62.74 40.41 35.42 26.61 36.95
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 1.81% 1.59% 2.47% 2.82% 3.76% 2.71%
Enterprise Value to Invested Capital (EV/IC)		 1.03 0.76 1.08 1.20 1.31 1.58 1.82 2.11 2.48 2.67 3.99
Enterprise Value to Revenue (EV/Rev)		 0.49 0.00 0.00 0.00 0.49 0.49 0.53 0.58 0.72 0.73 1.07
Enterprise Value to EBITDA (EV/EBITDA)		 11.60 0.00 0.00 0.00 13.11 12.05 13.91 14.58 19.83 18.60 24.71
Enterprise Value to EBIT (EV/EBIT)		 29.19 0.00 0.00 0.00 26.86 21.26 23.77 22.74 31.62 27.37 34.21
Enterprise Value to NOPAT (EV/NOPAT)		 41.70 0.00 0.00 0.00 38.37 26.98 37.79 29.13 41.62 34.13 40.78
Enterprise Value to Operating Cash Flow (EV/OCF)		 20.38 0.00 0.00 0.00 233.17 28.36 25.00 22.21 19.04 19.58 30.25
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 52.08 8.97 7.44 7.33 55.71 45.94 69.56
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 5.86 1.64 1.76 1.78 1.60 1.58 1.53 1.46 1.41 1.33 1.14
Long-Term Debt to Equity		 5.81 1.61 1.73 1.75 1.57 1.55 1.50 1.43 1.38 1.30 1.11
Financial Leverage		 5.84 1.61 1.75 1.76 2.72 1.38 1.42 1.36 1.11 1.02 0.98
Leverage Ratio		 9.03 3.59 3.49 3.57 5.06 3.52 3.45 3.44 3.49 3.28 3.14
Compound Leverage Factor		 -1.96 -31.03 0.56 0.05 1.55 0.62 0.69 1.94 2.24 2.24 2.25
Debt to Total Capital		 85.42% 62.18% 63.81% 64.00% 61.48% 61.27% 60.47% 59.33% 58.49% 57.09% 53.16%
Short-Term Debt to Total Capital		 0.77% 1.17% 1.10% 1.09% 1.14% 1.12% 1.15% 1.16% 1.15% 1.14% 0.94%
Long-Term Debt to Total Capital		 84.65% 61.01% 62.72% 62.91% 60.34% 60.16% 59.31% 58.17% 57.33% 55.95% 52.22%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.66% 0.16% 0.14% 0.10% 0.09% 0.07% 0.06% 0.05% 0.25% 0.23% 0.22%
Common Equity to Total Capital		 13.92% 37.66% 36.04% 35.90% 38.44% 38.65% 39.48% 40.62% 41.27% 42.68% 46.62%
Debt to EBITDA		 9.69 0.00 0.00 0.00 6.23 5.57 5.53 5.00 5.65 4.92 3.77
Net Debt to EBITDA		 9.65 0.00 0.00 0.00 6.09 5.46 5.39 4.73 5.46 3.27 2.88
Long-Term Debt to EBITDA		 9.60 0.00 0.00 0.00 6.12 5.46 5.43 4.90 5.53 4.82 3.70
Debt to NOPAT		 34.83 0.00 0.00 0.00 18.24 12.46 15.03 9.98 11.85 9.02 6.22
Net Debt to NOPAT		 34.70 0.00 0.00 0.00 17.82 12.22 14.63 9.45 11.45 5.99 4.75
Long-Term Debt to NOPAT		 34.52 0.00 0.00 0.00 17.91 12.24 14.74 9.78 11.61 8.84 6.11
Altman Z-Score		 1.72 0.10 0.35 0.43 2.40 2.69 2.92 3.21 3.14 3.66 4.73
Noncontrolling Interest Sharing Ratio		 4.54% 0.43% 0.39% 0.27% 1.39% 0.31% 0.26% 0.20% 0.42% 0.37% 0.32%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.17 1.26 1.33 1.35 1.33 1.73 1.76 1.79 1.57 1.74 1.59
Quick Ratio		 0.72 0.84 0.88 0.84 0.76 0.71 0.69 0.74 0.58 1.29 1.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4,099 -4,291 -5,117 12 483 767 858 20 33 -35
Operating Cash Flow to CapEx		 964.71% -361.47% -64.12% 135.94% 591.81% 576.21% 200.93% 684.79% 614.79% 570.66% 151.27%
Free Cash Flow to Firm to Interest Expense		 0.00 -52.72 -81.83 -91.27 0.22 11.57 19.77 22.44 0.53 0.87 -0.94
Operating Cash Flow to Interest Expense		 1.96 -1.01 -0.29 0.49 1.65 2.43 1.27 2.82 6.01 3.18 1.19
Operating Cash Flow Less CapEx to Interest Expense		 1.75 -1.29 -0.74 0.13 1.37 2.01 0.64 2.41 5.03 2.63 0.40
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.60 0.00 0.00 0.00 1.97 2.06 2.18 2.25 2.09 2.26 2.41
Accounts Receivable Turnover		 10.01 0.00 0.00 0.00 11.80 12.06 12.84 13.05 13.64 13.07 13.61
Inventory Turnover		 18.35 0.00 0.00 0.00 18.55 22.54 21.75 20.64 15.70 21.91 20.98
Fixed Asset Turnover		 35.89 0.00 0.00 0.00 45.41 56.08 59.40 62.74 67.02 71.99 73.43
Accounts Payable Turnover		 11.52 0.00 0.00 0.00 12.23 13.42 13.30 13.27 10.64 12.23 12.25
Days Sales Outstanding (DSO)		 36.46 0.00 0.00 0.00 30.94 30.25 28.42 27.97 26.75 27.94 26.82
Days Inventory Outstanding (DIO)		 19.89 0.00 0.00 0.00 19.67 16.20 16.78 17.68 23.26 16.66 17.40
Days Payable Outstanding (DPO)		 31.68 0.00 0.00 0.00 29.85 27.20 27.44 27.50 34.31 29.84 29.80
Cash Conversion Cycle (CCC)		 24.67 0.00 0.00 0.00 20.77 19.25 17.76 18.15 15.70 14.75 14.42
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4,188 4,104 4,413 4,461 4,226 3,673 3,688 3,670 3,769 3,749 3,844
Invested Capital Turnover		 2.11 0.00 0.00 0.00 2.68 3.05 3.10 3.27 3.45 3.68 3.82
Increase / (Decrease) in Invested Capital		 0.00 4,104 4,413 4,461 38 -431 -724 -792 57 75 155
Enterprise Value (EV)		 4,296 3,117 4,759 5,364 5,543 5,791 6,712 7,755 9,335 10,016 15,319
Market Capitalization		 693 580 1,946 2,517 2,965 3,165 4,110 5,237 6,754 8,247 13,524
Book Value per Share		 $4.96 $8.93 $9.34 $9.42 $9.46 $9.64 $10.00 $10.27 $10.40 $10.23 $10.56
Tangible Book Value per Share		 ($24.65) ($10.81) ($10.96) ($11.08) ($10.54) ($7.15) ($6.72) ($6.06) ($6.81) ($5.64) ($5.16)
Total Capital		 4,201 4,163 4,438 4,497 4,287 4,365 4,415 4,477 4,544 4,637 4,394
Total Debt		 3,588 2,588 2,832 2,878 2,636 2,675 2,670 2,656 2,658 2,648 2,336
Total Long-Term Debt		 3,556 2,540 2,783 2,829 2,587 2,626 2,619 2,605 2,605 2,595 2,295
Net Debt		 3,575 2,530 2,807 2,842 2,574 2,623 2,599 2,516 2,569 1,759 1,786
Capital Expenditures (CapEx)		 17 22 24 20 15 18 24 16 38 22 29
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 227 318 400 459 452 1,067 1,123 1,142 1,009 305 405
Debt-free Net Working Capital (DFNWC)		 240 376 426 495 513 1,120 1,193 1,282 1,097 1,194 956
Net Working Capital (NWC)		 208 328 377 446 465 1,071 1,143 1,230 1,045 1,141 914
Net Nonoperating Expense (NNE)		 55 52 102 -646 35 23 15 11 -0.33 -40 37
Net Nonoperating Obligations (NNO)		 3,575 2,530 2,807 2,842 2,574 1,983 1,943 1,849 1,883 1,759 1,786
Total Depreciation and Amortization (D&A)		 56 53 53 53 58 45 45 44 42 42 44
Debt-free, Cash-free Net Working Capital to Revenue		 2.58% 0.00% 0.00% 0.00% 4.01% 9.00% 8.94% 8.58% 7.82% 2.24% 2.82%
Debt-free Net Working Capital to Revenue		 2.72% 0.00% 0.00% 0.00% 4.56% 9.44% 9.50% 9.64% 8.50% 8.75% 6.65%
Net Working Capital to Revenue		 2.36% 0.00% 0.00% 0.00% 4.12% 9.03% 9.09% 9.25% 8.09% 8.36% 6.36%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.05) ($0.26) $0.10 ($0.04) $0.11 $0.15 $0.14 $0.27 $0.38 $0.73 $0.41
Adjusted Weighted Average Basic Shares Outstanding		 117.87M 175.53M 197.52M 198.49M 193.00M 201.01M 201.81M 203.49M 202.56M 204.71M 206.04M
Adjusted Diluted Earnings per Share		 ($0.05) ($0.26) $0.10 ($0.04) $0.11 $0.14 $0.13 $0.26 $0.34 $0.67 $0.38
Adjusted Weighted Average Diluted Shares Outstanding		 117.87M 175.53M 208.99M 198.49M 193.00M 214.93M 216.34M 217.98M 219.77M 221.32M 220.28M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 171.32M 171.46M 174.13M 174.97M 174.25M 177.15M 180.35M 193.54M 193.92M 197.86M
Normalized Net Operating Profit after Tax (NOPAT)		 48 5.65 44 40 50 36 42 66 77 109 121
Normalized NOPAT Margin		 2.01% 0.22% 1.60% 1.37% 1.65% 1.23% 1.35% 1.99% 2.17% 3.01% 3.12%
Pre Tax Income Margin		 -0.62% -2.70% 0.37% 0.03% 0.79% 0.31% 0.31% 1.49% 1.96% 2.29% 2.41%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.82 0.10 1.19 1.01 1.44 1.21 1.25 2.30 2.81 3.15 3.54
NOPAT to Interest Expense		 0.58 0.07 2.32 -11.69 0.92 1.25 1.09 1.74 2.00 2.82 3.27
EBIT Less CapEx to Interest Expense		 0.62 -0.18 0.74 0.66 1.16 0.79 0.62 1.89 1.83 2.59 2.75
NOPAT Less CapEx to Interest Expense		 0.37 -0.21 1.87 -12.05 0.64 0.83 0.46 1.32 1.02 2.26 2.49
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.41% 0.00% 0.00% 0.00% -14.45% 13.56% 11.30% 4.01% 25.53% 33.42% 44.73%

Financials Breakdown Chart

Key Financial Trends

BrightSpring Health Services (NASDAQ:BTSG) has shown strong revenue growth and a significant improvement in profitability since 2023, although its latest quarter reflected weaker cash generation and continued balance-sheet leverage. The comparison is based on the quarterly data provided, which spans Q1 2023 through Q2 2026 rather than a complete four-year history.

  • Revenue growth remains a major strength. Q2 2026 revenue increased to $3.87 billion from $2.17 billion in Q2 2023, an approximately 79% increase. Revenue also rose 8.5% from Q1 2026 and 23.0% from Q2 2025.
  • Operating profitability has improved substantially in dollar terms. Operating income reached $130.4 million in Q2 2026, compared with $48.6 million in Q2 2025 and a $15.3 million operating loss in Q1 2024.
  • Continuing-operations earnings have strengthened. Net income from continuing operations increased to $86.6 million in Q2 2026 from $74.3 million in Q1 2026 and $8.5 million in Q2 2025. Diluted EPS was $0.38, up from $0.13 a year earlier.
  • BrightSpring has generated positive operating cash flow in every reported quarter since Q3 2024. Operating cash flow was $43.9 million in Q2 2026, following $122.9 million in Q1 2026 and $231.6 million in Q4 2025. This is a meaningful improvement from the negative $15.2 million reported in Q2 2024.
  • Debt reduction continued in Q2 2026. Short- and long-term debt, excluding capital leases, declined to approximately $2.19 billion from $2.50 billion in Q1 2026 and $2.55 billion in Q2 2025. The company repaid $311.5 million of debt during the latest quarter.
  • Share repurchases have supported shareholder returns. BrightSpring repurchased approximately $60.3 million of common equity in Q2 2026, following $60.0 million in Q1 2026. These buybacks may help offset dilution from equity issuance and employee compensation.
  • Liquidity is adequate but not excessive. Cash and equivalents totaled $550.4 million at June 30, 2026, while current assets of $2.47 billion exceeded current liabilities of $1.56 billion. However, cash declined sharply from $888.8 million at the end of Q1 2026.
  • Recent earnings comparisons require caution. Q2 2025 and Q1 2025 figures were restated, and discontinued operations materially affected reported net income in several periods. Investors should focus on continuing operations and review future filings for comparability.
  • Cash generation weakened in the latest quarter. Q2 2026 operating cash flow of $43.9 million was down from $122.9 million in Q1 2026 and $49.1 million in Q2 2025. A $116.8 million use of cash from operating assets and liabilities was the primary drag.
  • Leverage and interest costs remain significant risks. Including capital lease obligations, debt was approximately $2.64 billion at June 30, 2026, while the company paid $32.7 million of cash interest during Q2. Goodwill and intangible assets totaled approximately $3.05 billion, or roughly half of total assets, increasing impairment risk if operating performance deteriorates.

Overall, the trend is improving but uneven. BrightSpring has delivered rapid top-line expansion, returned to stronger operating profitability and reduced debt. The main issues for investors to monitor are the recent decline in cash, volatile working-capital requirements, high leverage and the company’s ability to convert growing revenue into consistent free cash flow.

09/04/26 02:29 PM ETAI Generated. May Contain Errors.

BrightSpring Health Services Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BrightSpring Health Services' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

BrightSpring Health Services' net income appears to be on a downward trend, with a most recent value of $189.11 million in 2025, falling from -$54.22 million in 2022. The previous period was -$20.52 million in 2024. See BrightSpring Health Services' forecast for analyst expectations on what's next for the company.

BrightSpring Health Services' total operating income in 2025 was $295.25 million, based on the following breakdown:
  • Total Gross Profit: $1.52 billion
  • Total Operating Expenses: $1.22 billion

Over the last 3 years, BrightSpring Health Services' total revenue changed from $7.72 billion in 2022 to $12.91 billion in 2025, a change of 67.2%.

BrightSpring Health Services' total liabilities were at $4.53 billion at the end of 2025, a 5.9% increase from 2024, and a 8.0% decrease since 2023.

In the past 2 years, BrightSpring Health Services' cash and equivalents has ranged from $13.07 million in 2023 to $88.37 million in 2025, and is currently $88.37 million as of their latest financial filing in 2025.

Over the last 3 years, BrightSpring Health Services' book value per share changed from 0.00 in 2022 to 10.40 in 2025, a change of 1,039.7%.


Related Companies

Financial statements for NASDAQ:BTSG last updated on 7/31/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A Tiny Gold Property Borders Barrick's Massive Nevada Discoveries
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Anthropic’s $65 Billion Surge: One backdoor got there first
Anthropic's annualized revenue run rate hit $65 billion, up from $47 billion in May and roughly $9 billion at ...
The Oxford Club | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
American retirees will miss THIS. Big Banks just moved in.
Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...
Cedar Gold Group | Sponsoredtc pixel
FDA Momentum is Building Around NNVC!
NanoViricides (NYSE: NNVC) just received regulatory approval to begin a Phase II trial of NV-387 Oral Gummies ...
Smallcaps Daily | Sponsoredtc pixel